Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.690
-0.040 (-2.31%)
At close: Aug 1, 2025, 4:00 PM
1.670
-0.020 (-1.18%)
After-hours: Aug 1, 2025, 6:47 PM EDT

Company Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.

The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.

The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.

Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Heron Therapeutics, Inc.
Heron Therapeutics logo
CountryUnited States
Founded1983
IPO DateAug 26, 1987
IndustryBiotechnology
SectorHealthcare
Employees122
CEOCraig Collard

Contact Details

Address:
100 Regency Forest Drive, Suite 300
Cary, North Carolina 27518
United States
Phone(858) 251-4400
Websiteherontx.com

Stock Details

Ticker SymbolHRTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000818033
CUSIP Number427746102
ISIN NumberUS4277461020
Employer ID94-2875566
SIC Code2834

Key Executives

NamePosition
Craig Alexander CollardChief Executive Officer and Director
Ira DuarteExecutive Vice President and Chief Financial Officer
Dr. William P. Forbes Pharm. D., Pharm.D.Executive Vice President and Chief Development Officer
Mark E. HensleyExecutive Vice President and Chief Operating Officer
Melissa JarelExecutive Director of Legal
Ryan CraigVice President of Marketing
John AikenExecutive Director of People Management and Training
Dr. John C. Arthur Ph.D.Senior Vice President of Manufacturing and Supply
Robert SullivanSenior Vice President of Oncology Care Franchise and Commercial Operations
Brett FleshmanChief Business Officer

Latest SEC Filings

DateTypeTitle
Jun 18, 20258-KCurrent Report
May 6, 2025S-8Securities to be offered to employees in employee benefit plans
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
May 6, 20258-KCurrent Report
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025ARSFiling
Apr 30, 2025DEF 14AOther definitive proxy statements
Apr 29, 20258-KCurrent Report
Feb 27, 202510-KAnnual Report